Pacira Pharmaceuticals (PCRX) Receives a Buy from Wedbush

Wedbush analyst Liana Moussatos reiterated a Buy rating on Pacira Pharmaceuticals (PCRXResearch Report) today and set a price target of $85. The company’s shares opened today at $43.50.

According to TipRanks.com, Moussatos ‘ ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -9.6% and a 30.7% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical Inc., Aquestive Therapeutics Inc, and Allena Pharmaceuticals Inc.

Currently, the analyst consensus on Pacira Pharmaceuticals is a Moderate Buy with an average price target of $54.56, implying a 25.4% upside from current levels. In a report released yesterday, Barclays also initiated coverage with a Buy rating on the stock with a $52 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $55 and a one-year low of $30. Currently, Pacira Pharmaceuticals has an average volume of 569.7K.

Based on the recent corporate insider activity of 56 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Pacira Biosciences, Inc. operates as a holding company, which engages in the development, commercialization, and manufacture of pharmaceutical products for use in postsurgical outcomes for acute care practitioners and their patients.